Compare Orchid Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA vs GSK PHARMA - Comparison Results

ORCHID PHARMA     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA GSK PHARMA ORCHID PHARMA/
GSK PHARMA
 
P/E (TTM) x -133.2 51.6 - View Chart
P/BV x 38.2 11.6 328.3% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 ORCHID PHARMA   GSK PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA
Sep-13
GSK PHARMA
Mar-19
ORCHID PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1943,595 5.4%   
Low Rs351,253 2.8%   
Sales per share (Unadj.) Rs276.5184.7 149.7%  
Earnings per share (Unadj.) Rs-79.226.3 -301.3%  
Cash flow per share (Unadj.) Rs-43.529.2 -149.0%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs53.9126.3 42.7%  
Shares outstanding (eoy) m70.45169.40 41.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.413.1 3.2%   
Avg P/E ratio x-1.492.2 -1.6%  
P/CF ratio (eoy) x-2.683.1 -3.2%  
Price / Book Value ratio x2.119.2 11.1%  
Dividend payout %076.1 0.0%   
Avg Mkt Cap Rs m8,067410,626 2.0%   
No. of employees `0002.85.0 56.5%   
Total wages/salary Rs m2,5275,372 47.0%   
Avg. sales/employee Rs Th6,956.16,306.7 110.3%   
Avg. wages/employee Rs Th902.51,083.1 83.3%   
Avg. net profit/employee Rs Th-1,993.0898.0 -221.9%   
INCOME DATA
Net Sales Rs m19,47731,281 62.3%  
Other income Rs m4071,023 39.8%   
Total revenues Rs m19,88432,304 61.6%   
Gross profit Rs m1,1036,009 18.3%  
Depreciation Rs m2,519486 518.4%   
Interest Rs m5,2276 87,113.3%   
Profit before tax Rs m-6,2366,540 -95.4%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511287 178.0%   
Tax Rs m-1252,373 -5.3%   
Profit after tax Rs m-5,5804,454 -125.3%  
Gross profit margin %5.719.2 29.5%  
Effective tax rate %2.036.3 5.5%   
Net profit margin %-28.714.2 -201.2%  
BALANCE SHEET DATA
Current assets Rs m11,01420,061 54.9%   
Current liabilities Rs m32,06014,543 220.4%   
Net working cap to sales %-108.117.6 -612.5%  
Current ratio x0.31.4 24.9%  
Inventory Days Days9557 167.1%  
Debtors Days Days3414 238.7%  
Net fixed assets Rs m29,44014,343 205.3%   
Share capital Rs m7051,694 41.6%   
"Free" reserves Rs m2,04319,704 10.4%   
Net worth Rs m3,80021,398 17.8%   
Long term debt Rs m9,0182 450,895.0%   
Total assets Rs m46,51039,113 118.9%  
Interest coverage x-0.21,091.0 -0.0%   
Debt to equity ratio x2.40 2,539,114.7%  
Sales to assets ratio x0.40.8 52.4%   
Return on assets %-0.811.4 -6.7%  
Return on equity %-146.920.8 -705.5%  
Return on capital %-3.731.9 -11.7%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,513534 1,407.0%   
Fx outflow Rs m5,6497,091 79.7%   
Net fx Rs m1,865-6,557 -28.4%   
CASH FLOW
From Operations Rs m1,6823,994 42.1%  
From Investments Rs m-9,860-1,433 687.9%  
From Financial Activity Rs m6,644-3,584 -185.4%  
Net Cashflow Rs m-1,535-1,023 150.0%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 4.6 10.2 45.1%  
FIIs % 3.3 23.8 13.9%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 15.4 359.1%  
Shareholders   84,811 102,036 83.1%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  FDC  ASTRAZENECA PHARMA  BIOCON   

Compare ORCHID PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA SHARE PRICE


Apr 16, 2021 (Close)

TRACK ORCHID PHARMA

  • Track your investment in ORCHID PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ORCHID PHARMA 8-QTR ANALYSIS

COMPARE ORCHID PHARMA WITH

MARKET STATS